Browse

Big healthcare organizations are increasingly building their own AI tools, rather than shelling out for tools made by health tech startups that may eventually become free. It’s not uncommon to find…

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.